Covid-19-research
-
Possible COVID-19 “decoy”
It might be possible to use vesicles carrying the receptor for SARS-CoV-2, the virus that causes COVID-19, to bind the virus and prevent infection. Read MoreOct 15, 2020
-
COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca. Read MoreOct 13, 2020
-
Vanderbilt researchers develop publicly available COVID-19 animal susceptibility prediction tool; suggests increased risk to horses
All-remote collaboration results in free animal susceptibility tool to help prioritize research and closer examination of at-risk species. Read MoreOct 6, 2020
-
VUMC awarded $34 million to lead nationwide convalescent plasma study
Vanderbilt University Medical Center has been awarded a one-year, $34-million grant by the National Center for Advancing Translational Sciences, part of the National Institutes of Health, to conduct a nationwide study of “convalescent plasma” as a treatment for COVID-19. Read MoreSep 20, 2020